We are pleased to share the findings from our recent Phase 1 study, which investigated the potential of Zilebesiran, an investigational RNA interference therapeutic. The study focused on patients with Class II/III obesity and hypertension, and the results are exceptionally promising:

  • Serum AGT Reduction: Sequential doses of Zilebesiran led to an impressive 99% reduction in serum angiotensinogen (AGT) levels.
  • Blood Pressure Improvement: Sustained reductions in blood pressure, with a decrease of -27 ± 8 mmHg from baseline to week 24.
  • Safety and Tolerance: Zilebesiran was generally well-tolerated, with only minimal adverse events reported.

These results suggest that the pharmacodynamics, efficacy, and safety of Zilebesiran may not be influenced by BMI, offering new hope in the treatment of hypertension, especially in obese patients.

For more details on this ground breaking research, please visit https://www.researchgate.net/publication/374657385_Abstract_116_Safety_And_Tolerability_Of_Zilebesiran_An_RNA_Interference_Therapeutic_Targeting_Hepatic_Angiotensinogen_Synthesis_In_Obese_Patients_With_Hypertension

NOTE: Angiotensinogen(AGT) is a protein that is part of the renin-angiotensin system. This system regulates blood pressure and the balance of fluids and salts in the body1. Angiotensinogen is produced by the liver and secreted into the bloodstream. Itis converted to angiotensin I, which is then converted to angiotensin II. Angiotensin II causes blood vessels to narrow, which results in increased blood pressure. This molecule also stimulates the production of the hormone aldosterone, which triggers the absorption of salt and water by the kidneys.

Latest news

A first of a kind trial in the fight against malaria

June 12, 2024
Richmond successfully recruits and enrols adults of sub-Saharan ancestry who all complete a first of its kind trial in the treatment of malaria.
Read more

Patient with rare bleeding disorder becomes first to test new treatment

May 22, 2024
The thousands of patients who participate in Richmond’s trials are helping to advance medical science and save lives and, in the process, some make history. In a film released today, one trial participant tells her story.
Read more


AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event